Template:Congestive heart failure: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi (talk | contribs) No edit summary |
No edit summary |
||
(35 intermediate revisions by 8 users not shown) | |||
Line 1: | Line 1: | ||
{| class="infobox bordered" style="width: | {| class="infobox bordered" style="width:15%; text-align:left; font-size:90%; background:AliceBlue" | ||
|- | |- | ||
| colspan="1" style="text-align:center; background:DarkGray" | | | colspan="1" style="text-align:center; background:DarkGray" |'''Congestive Heart Failure Microchapters''' | ||
|- bgcolor="LightGrey" | |- bgcolor="LightGrey" | ||
! | ! | ||
Line 23: | Line 22: | ||
! | ! | ||
[[Congestive heart failure overview|Overview]] | [[Congestive heart failure overview|Overview]] | ||
|- | |||
! | |||
|- bgcolor="Pink" | |||
! | |||
[[Congestive heart failure historical perspective|Historical Perspective]] | |||
|- | |- | ||
! | ! | ||
Line 34: | Line 39: | ||
|- bgcolor="Pink" | |- bgcolor="Pink" | ||
! | ! | ||
[[Congestive heart failure pathophysiology| | Pathophysiology | ||
:[[Congestive heart failure pathophysiology#Systolic dysfunction|Systolic Dysfunction]] | |||
:[[Diastolic dysfunction pathophysiology|Diastolic Dysfunction]] | |||
:[[Congestive heart failure with preserved EF|HFpEF]] | |||
:[[Congestive heart failure with reduced EF|HFrEF]] | |||
|- | |- | ||
! | ! | ||
Line 43: | Line 52: | ||
|- | |- | ||
! | ! | ||
|- bgcolor="Pink" | |- bgcolor="Pink" | ||
! | ! | ||
Line 48: | Line 58: | ||
|- | |- | ||
! | ! | ||
|- bgcolor="Pink" | |- bgcolor="Pink" | ||
! | ! | ||
Line 57: | Line 68: | ||
! | ! | ||
[[Congestive heart failure risk factors|Risk Factors]] | [[Congestive heart failure risk factors|Risk Factors]] | ||
|- | |||
! | |||
|- bgcolor="Pink" | |||
! | |||
[[Congestive heart failure Screening|Screening]] | |||
|- | |- | ||
! | ! | ||
Line 107: | Line 124: | ||
|- | |- | ||
! | ! | ||
|- bgcolor="LightSkyBlue" | |- bgcolor="LightSkyBlue" | ||
! | ! | ||
Line 112: | Line 130: | ||
|- | |- | ||
! | ! | ||
|- bgcolor="LightSkyBlue" | |- bgcolor="LightSkyBlue" | ||
! | ! | ||
Line 138: | Line 157: | ||
|- bgcolor="LightSkyBlue" | |- bgcolor="LightSkyBlue" | ||
! | ! | ||
[[Congestive heart failure | [[Congestive heart failure Other Imaging Studies|Other Imaging Studies]] | ||
|- | |||
! | |||
|- bgcolor="LightSkyBlue" | |||
! | |||
[[Congestive heart failure other diagnostic studies|Other Diagnostic Studies]] | |||
|- | |- | ||
! | ! | ||
Line 157: | Line 182: | ||
! | ! | ||
Medical Therapy: | Medical Therapy: | ||
|- bgcolor="PaleTurquoise" | |||
! | |||
: [[Congestive heart failure pharmacotherapy|Summary]] | |||
|- bgcolor="PaleTurquoise" | |||
! | |||
: [[Congestive heart failure acute pharmacotherapy|Acute Pharmacotherapy]] | : [[Congestive heart failure acute pharmacotherapy|Acute Pharmacotherapy]] | ||
: [[Chronic Pharmacotherapy]]: | |- bgcolor="PaleTurquoise" | ||
! | |||
: [[Congestive heart failure with preserved EF pharmacotherapy|Chronic Pharmacotherapy in HFpEF]] | |||
|- bgcolor="PaleTurquoise" | |||
! | |||
: [[Congestive heart failure chronic pharmacotherapy|Chronic Pharmacotherapy in HFrEF]] | |||
:: [[Congestive heart failure diuretics|Diuretics]] | :: [[Congestive heart failure diuretics|Diuretics]] | ||
:: [[Congestive heart failure ACE inhibitors|ACE Inhibitors]] | :: [[Congestive heart failure ACE inhibitors|ACE Inhibitors]] | ||
Line 169: | Line 204: | ||
:: [[Congestive heart failure positive inotropics|Positive Inotropics]] | :: [[Congestive heart failure positive inotropics|Positive Inotropics]] | ||
:: [[Congestive heart failure anticoagulants|Anticoagulants]] | :: [[Congestive heart failure anticoagulants|Anticoagulants]] | ||
:: [[Congestive heart failure angiotensin receptor-neprilysin inhibitor|Angiotensin Receptor-Neprilysin Inhibitor]] | |||
:: [[Congestive heart failure antiarrhythmic Drugs|Antiarrhythmic Drugs]] | :: [[Congestive heart failure antiarrhythmic Drugs|Antiarrhythmic Drugs]] | ||
:: [[Congestive heart failure other pharmacotherapies#Nutritional Supplements|Nutritional Supplements]] | :: [[Congestive heart failure other pharmacotherapies#Nutritional Supplements|Nutritional Supplements]] | ||
:: [[Congestive heart failure other pharmacotherapies#Hormonal Therapies|Hormonal Therapies]] | :: [[Congestive heart failure other pharmacotherapies#Hormonal Therapies|Hormonal Therapies]] | ||
:[[Congestive heart failure drugs to avoid|Drugs to Avoid]] | :[[Congestive heart failure drugs to avoid|Drugs to Avoid]] | ||
Line 200: | Line 235: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
ACC/AHA Guideline Recommendations | |||
: [[ | : [[Congestive heart failure AHA recommendations|Initial and Serial Evaluation of the HF Patient]] | ||
: [[Congestive heart failure AHA recommendations for hospitalized patient|Hospitalized Patient]] | |||
: [[Congestive heart failure AHA recommendations for hospitalized patient|Hospitalized | |||
: [[Congestive heart failure AHA recommendations for patients with a prior MI|Patients With a Prior MI]] | : [[Congestive heart failure AHA recommendations for patients with a prior MI|Patients With a Prior MI]] | ||
: [[Congestive heart failure sudden cardiac death prevention|Sudden Cardiac Death Prevention]] | : [[Congestive heart failure sudden cardiac death prevention|Sudden Cardiac Death Prevention]] | ||
: [[Congestive heart failure AHA recommendations Surgical/Percutaneous/Transcather Interventional Treatments of HF|Surgical/Percutaneous/Transcather Interventional Treatments of HF]] | |||
: [[Congestive heart failure treatment of patients at high risk for developing heart failure (Stage A)|Patients at high risk for developing heart failure (Stage A)]] | : [[Congestive heart failure treatment of patients at high risk for developing heart failure (Stage A)|Patients at high risk for developing heart failure (Stage A)]] | ||
: [[Congestive heart failure treatment of patients with cardiac structural abnormalities or remodeling who have not developed heart failure symptoms (Stage B)|Patients with cardiac structural abnormalities or remodeling who have not developed heart failure symptoms (Stage B)]] | : [[Congestive heart failure treatment of patients with cardiac structural abnormalities or remodeling who have not developed heart failure symptoms (Stage B)|Patients with cardiac structural abnormalities or remodeling who have not developed heart failure symptoms (Stage B)]] | ||
: [[Congestive heart failure treatment of patients with current or prior symptoms of heart failure (Stage C)|Patients with current or prior symptoms of heart failure (Stage C)]] | : [[Congestive heart failure treatment of patients with current or prior symptoms of heart failure (Stage C)|Patients with current or prior symptoms of heart failure (Stage C)]] | ||
: [[Congestive heart failure treatment of patients with refractory end-stage heart failure (Stage D)|Patients with refractory end-stage heart failure (Stage D)]] | : [[Congestive heart failure treatment of patients with refractory end-stage heart failure (Stage D)|Patients with refractory end-stage heart failure (Stage D)]] | ||
: [[Congestive heart failure AHA recommendations Coordinating Care for Patients With Chronic HF|Coordinating Care for Patients With Chronic HF]] | |||
: [[Congestive heart failure AHA recommendations Quality Metrics/Performance Measures|Quality Metrics/Performance Measures]] | |||
|- | |- | ||
! | ! | ||
Line 244: | Line 268: | ||
: [[Congestive heart failure treatment of patients who have concomitant disorders|Patients who have concomitant disorders]] | : [[Congestive heart failure treatment of patients who have concomitant disorders|Patients who have concomitant disorders]] | ||
: [[Congestive heart failure and obstructive sleep apnea|Obstructive Sleep Apnea in the Patient with CHF]] | : [[Congestive heart failure and obstructive sleep apnea|Obstructive Sleep Apnea in the Patient with CHF]] | ||
: [[Unstable angina / non ST elevation myocardial infarction Heart Failure and Cardiogenic Shock|NSTEMI with Heart Failure and Cardiogenic Shock]] | |||
|- | |- | ||
! | ! | ||
Line 327: | Line 352: | ||
|- bgcolor="LightYellow" | |- bgcolor="LightYellow" | ||
! | ! | ||
[http://blogsearch.google.com/blogsearch?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&ie=UTF-8&oe=utf-8&rls=org.mozilla:en-US:official&client=firefox-a&um=1&sa=N&tab=wb Blogs on {{PAGENAME}}] | [http://blogsearch.google.com/blogsearch?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&ie=UTF-8&oe=utf-8&rls=org.mozilla:en-US:official&client=firefox-a&um=1&sa=N&tab=wb Blogs on {{PAGENAME}}] | ||
|- | |- | ||
! | ! | ||
Line 343: | Line 368: | ||
! | ! | ||
|- | |||
|} | |} |
Latest revision as of 17:06, 23 December 2019
Congestive Heart Failure Microchapters |
Pathophysiology |
---|
Differentiating Congestive heart failure from other Diseases |
Diagnosis |
Treatment |
Medical Therapy: |
Surgical Therapy: |
ACC/AHA Guideline Recommendations
|
Specific Groups: |
Congestive heart failure On the Web |
Risk calculators and risk factors for Congestive heart failure |